[ad_1] Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. [ad_2] Source link
Tag: 4523.TO
Biogen Boss Turns Corner on Alzheimer’s Miscues
[ad_1] The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm. [ad_2] Source link
FDA Seeks More Data on Lilly’s Alzheimer’s Drug Candidate
[ad_1] Business Health Care Health Setback could delay potential commercial introduction by at least several months [ad_2] Source link
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
[ad_1] Pharmaceutical companies could try to blunt the limits on future price increases. [ad_2] Source link
FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug Aduhelm
[ad_1] Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company. [ad_2] Source link
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients
[ad_1] Health Medicare won’t pay for medicine under rule issued to restrict use of earlier drug whose approval generated controversy [ad_2] Source link
New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease
[ad_1] Health Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked to Alzheimer’s helped patients [ad_2] Source link